Aytu Biopharma, Inc (AYTU): Capital Expenditures
$29.0K
Year ended 2026-06-30
-19.5%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $29.0K | -87.3% | 2026-09-22, From 2025-07-01 |
| 2025-06-30 | $228.0K | -30.7% | 2026-09-22, From 2024-07-01 |
| 2024-06-30 | $329.0K | n/a | 2025-09-23, From 2023-07-01 |
| No annual figure between 2020-06-30 and 2024-06-30. | |||
| 2020-06-30 | $0 | -100.0% | 2020-10-06, From 2019-07-01 |
| 2019-06-30 | $59.8K | -19.9% | 2020-10-06, From 2018-07-01 |
| 2018-06-30 | $74.7K | -33.1% | 2019-09-26, From 2017-07-01 |
| 2017-06-30 | $111.6K | -55.9% | 2018-09-06, From 2016-07-01 |
| 2016-06-30 | $252.9K | n/a | 2017-08-31, From 2015-07-01 |
| 2015-06-30 | $0 | -100.0% | 2016-09-01, From 2014-07-01 |
| 2014-06-30 | $9.3K | n/a | 2015-09-28, From 2013-07-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $29.0K | -87.3% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $4.32M | +156.1% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $1.05M | +39.0% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $12.01M | +832.5% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $12.90M | -28.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $6.64M | n/m |
Compare AYTU, NKTR, AGIO, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗